SG11201907232XA - 2-heteroaryl-3-oxo-2,3-dihydropyridazine-4-carboxamides for the treatment of cancer - Google Patents
2-heteroaryl-3-oxo-2,3-dihydropyridazine-4-carboxamides for the treatment of cancerInfo
- Publication number
- SG11201907232XA SG11201907232XA SG11201907232XA SG11201907232XA SG11201907232XA SG 11201907232X A SG11201907232X A SG 11201907232XA SG 11201907232X A SG11201907232X A SG 11201907232XA SG 11201907232X A SG11201907232X A SG 11201907232XA SG 11201907232X A SG11201907232X A SG 11201907232XA
- Authority
- SG
- Singapore
- Prior art keywords
- berlin
- international
- compounds
- str
- dihydropyridazine
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title abstract 3
- 201000011510 cancer Diseases 0.000 title abstract 3
- 238000011282 treatment Methods 0.000 title abstract 3
- 150000001875 compounds Chemical class 0.000 abstract 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 abstract 2
- 230000001594 aberrant effect Effects 0.000 abstract 1
- 239000004480 active ingredient Substances 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 230000028993 immune response Effects 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 230000008520 organization Effects 0.000 abstract 1
- 238000011321 prophylaxis Methods 0.000 abstract 1
- 102220240796 rs553605556 Human genes 0.000 abstract 1
- 230000011664 signaling Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
- C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
- C07D237/04—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having less than three double bonds between ring members or between ring members and non-ring members
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
- C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
- C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D237/10—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D237/24—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Abstract
Filing Language: (26) Publication Language: (30) Priority Data: 17155406.6 17202882.1 02 February 2018 (02.02.2018) English English 09 February 2017 (09.02.2017) EP 21 November 2017 (21.11.2017) EP R 5 W N 0 I .0\" 0 © R . 0 0 2 H N 'IR O O 1-1 O 71- 1-1 3 (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date 16 August 2018 (16.08.2018) WIPO I PCT omit VIII °nolo olomiloollm Hollow° oimIE (10) International Publication Number WO 2018/146010 Al (51) International Patent Classification: C07D 401/14 (2006.01) C07D 409/04 (2006.01) C07D 405/14 (2006.01) C07D 413/04 (2006.01) C07D 401/04 (2006.01) CO7D 417/04 (2006.01) C07D 403/04 (2006.01) CO7D 417/14 (2006.01) C07D 237/04 (2006.01) A61K 31/501 (2006.01) C07D 237/24 (2006.01) A61P 35/00 (2006.01) (21) International Application Number: PCT/EP2018/052627 (22) International Filing Date: (71) Applicants: BAYER AKTIENGESELLSCHAFT [DE/DE]; Kaiser-Wilhelm-Allee 1, 51373 Lev- erkusen (DE). BAYER PHARMA AKTIENGESEL- LSCHAFT [DE/DE]; Miillerstr. 178, 13353 Berlin (DE). DEUTSCHES KREBSFORSCHUNGSZEN- TRUM [DE/DE]; Im Neuenheimer Feld 280, 69120 Hei- delberg (DE). (72) Inventors: GUTCHER, Ilona; Paul-Robeson-Str. 28, 10439 Berlin (DE). ROHN, Ulrike; Boyenstr. 42, 10115 Berlin (DE). SCHMEES, Norbert; Bondickstr. 61, 13469 Berlin (DE). ZORN, Ludwig; Osianderweg 45A, 13509 Berlin (DE). ROSE, Lars; Fuchsring 82, 13465 Berlin (DE). BADER, Benjamin; Hillmannstr. 14, 13467 Berlin (DE). KOBER, Christina; Heidelberger Str. 18, 76646 Bruchsal (DE). CARRETERO, Rafael; Milhlingstr. 6, 69121 Heidelberg (DE). STOCKIGT, Detlef; Clara- Zetkin-Str. 27, 14471 Potsdam (DE). IRLBACHER, Horst; Winsstr. 47, 10405 Berlin (DE). PLATTEN, Michael; Cambridgestr. 7, 69115 Heidelberg (DE). (74) Agent: BIP PATENTS; Alfred-Nobel-Str. 10, 40789 Mon- heim am Rhein (DE). (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). Declarations under Rule 4.17: — as to applicant's entitlement to apply for and be granted a patent (Rule 4.1700) Published: with international search report (Art. 21(3)) with sequence listing part of description (Rule 5.2(a)) 1-1 (54) Title: 2-HETEROARYL-3-OXO-2,3-DIHYDROPYRIDAZINE-4-CARBOXAMIDES FOR THE TREATMENT OF CANCER (57) : The present invention covers 2-heteroaryl-3-oxo-2,3-dihydropyridazine-4-carbox- amide compounds of general formula (I), in which X, R1, R 2 , R 3 , R4 and - lc 5 are as defined here- in, methods of preparing said compounds, intermediate compounds useful for preparing said com- pounds, pharmaceutical compositions and combinations comprising said compounds and the use of (I) said compounds for manufacturing pharmaceutical compositions for the treatment or prophylaxis of diseases, in particular of cancer or conditions with dysregulated immune responses or other dis- orders associated with aberrant AHR signaling, as a sole agent or in combination with other active ingredients.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP17155406 | 2017-02-09 | ||
| EP17202882 | 2017-11-21 | ||
| PCT/EP2018/052627 WO2018146010A1 (en) | 2017-02-09 | 2018-02-02 | 2-heteroaryl-3-oxo-2,3-dihydropyridazine-4-carboxamides for the treatment of cancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201907232XA true SG11201907232XA (en) | 2019-09-27 |
Family
ID=61188789
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201907232XA SG11201907232XA (en) | 2017-02-09 | 2018-02-02 | 2-heteroaryl-3-oxo-2,3-dihydropyridazine-4-carboxamides for the treatment of cancer |
Country Status (38)
| Country | Link |
|---|---|
| US (1) | US11795164B2 (en) |
| EP (1) | EP3580211B1 (en) |
| JP (1) | JP7128826B2 (en) |
| KR (1) | KR102627266B1 (en) |
| CN (3) | CN116554152A (en) |
| AU (1) | AU2018217860B2 (en) |
| BR (1) | BR112019016497A2 (en) |
| CA (1) | CA3052718A1 (en) |
| CL (1) | CL2019002255A1 (en) |
| CO (1) | CO2019008684A2 (en) |
| CR (1) | CR20190364A (en) |
| CU (1) | CU24564B1 (en) |
| CY (1) | CY1124484T1 (en) |
| DK (1) | DK3580211T3 (en) |
| DO (1) | DOP2019000206A (en) |
| EC (1) | ECSP19057713A (en) |
| ES (1) | ES2847162T3 (en) |
| GE (1) | GEP20217281B (en) |
| HR (1) | HRP20210143T1 (en) |
| HU (1) | HUE053191T2 (en) |
| IL (1) | IL268469B (en) |
| JO (1) | JOP20190193A1 (en) |
| LT (1) | LT3580211T (en) |
| MA (1) | MA47447B1 (en) |
| MX (1) | MX2019009571A (en) |
| NI (1) | NI201900085A (en) |
| PE (1) | PE20191496A1 (en) |
| PH (1) | PH12019501846A1 (en) |
| PL (1) | PL3580211T3 (en) |
| RS (1) | RS61401B1 (en) |
| SA (1) | SA519402422B1 (en) |
| SG (1) | SG11201907232XA (en) |
| SI (1) | SI3580211T1 (en) |
| TW (1) | TWI770113B (en) |
| UA (1) | UA124507C2 (en) |
| UY (1) | UY37606A (en) |
| WO (1) | WO2018146010A1 (en) |
| ZA (1) | ZA201905902B (en) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JOP20190193A1 (en) | 2017-02-09 | 2019-08-08 | Bayer Pharma AG | 2-heteroaryl-3-oxo-2,3-dihydropyridazine-4-carboxamides for the treatment of cancer |
| CN109813913B (en) * | 2019-01-31 | 2021-11-09 | 中国医学科学院肿瘤医院 | Use of aromatic hydrocarbon receptor (AhR) for predicting immunotherapy effect |
| EP3715471A1 (en) | 2019-03-29 | 2020-09-30 | Deutsches Krebsforschungszentrum, Stiftung des öffentlichen Rechts | Ahr signature marker set |
| EP3721894A1 (en) | 2019-04-10 | 2020-10-14 | Deutsches Krebsforschungszentrum, Stiftung des öffentlichen Rechts | Interleukin-4-induced gene 1 (il4i1) as a biomarker and uses thereof |
| CN112724256B (en) * | 2019-10-28 | 2022-09-16 | 中国农业大学 | High-stability sulfonamide antibody hAb4D11 and application thereof |
| EP3835432A1 (en) | 2019-12-10 | 2021-06-16 | Deutsches Krebsforschungszentrum, Stiftung des öffentlichen Rechts | Interleukin-4-induced gene 1 (il4i1) and respective metabolites as biomarkers for cancer |
| IL293861A (en) * | 2019-12-16 | 2022-08-01 | Bayer Ag | Combination of an ahr-inhibitor and an pd1-inhibitor antibody and its use in the treatment of cancer |
| AU2021226411A1 (en) | 2020-02-26 | 2022-09-22 | Jaguahr Therapeutics Pte Ltd | Pyridopyrimidine derivatives useful in modulation of AhR signalling |
| MX2022011826A (en) * | 2020-03-27 | 2022-10-18 | Dong A St Co Ltd | Aminopyrimidine derivatives and their use as aryl hydrocarbon receptor modulators. |
| CN114181212B (en) * | 2020-09-15 | 2023-06-06 | 山东轩竹医药科技有限公司 | Pyridazinone AhR inhibitors |
| WO2022078356A1 (en) * | 2020-10-15 | 2022-04-21 | 山东轩竹医药科技有限公司 | Heteroaromatic ahr inhibitor |
| CN114539221A (en) * | 2020-11-27 | 2022-05-27 | 苏州泽璟生物制药股份有限公司 | Deuterated 2-heteroaromatic-3-oxo-2, 3-dihydropyridazine-4-formamide inhibitor as well as preparation method and application thereof |
| CN114685426A (en) * | 2020-12-28 | 2022-07-01 | 苏州泽璟生物制药股份有限公司 | Sulfonamide inhibitor and preparation method and application thereof |
| CN114835687B (en) * | 2021-04-02 | 2023-09-05 | 北京华森英诺生物科技有限公司 | AhR inhibitors |
| WO2023043753A1 (en) * | 2021-09-14 | 2023-03-23 | Allianthera (Suzhou) Biopharmaceutical Co., Ltd. | 2-aryl or heteroaryl-3-oxo-4-carbamide-6-cyclic-dihydropyrazine aryl hydrocarbon receptor modulators and their use in the treatment of diseases and disorders |
| CA3234634A1 (en) | 2021-10-20 | 2023-04-27 | University Of Rochester | Compositions and methods for treating myelin deficiency by rejuvenating glial progenitor cells |
| WO2024076300A1 (en) | 2022-10-03 | 2024-04-11 | Jaguahr Therapeutics Pte Ltd | Compounds useful in modulation of ahr signalling |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE4134467A1 (en) | 1991-10-18 | 1993-04-22 | Thomae Gmbh Dr K | HETEROBIARYL DERIVATIVES, MEDICAMENTS CONTAINING THESE COMPOUNDS AND METHOD FOR THE PRODUCTION THEREOF |
| WO2000009488A1 (en) * | 1998-08-14 | 2000-02-24 | Nihon Nohyaku Co., Ltd. | Pyridazinone derivatives |
| JP2000119257A (en) | 1998-08-14 | 2000-04-25 | Nippon Nohyaku Co Ltd | Pyridazinone derivative |
| US20030225081A1 (en) | 2000-09-18 | 2003-12-04 | Satoshi Nagato | Pyridazinones and triazinones and medicinal use thereof |
| FR2847253B1 (en) | 2002-11-19 | 2007-05-18 | Aventis Pharma Sa | NOVEL DERIVATIVES OF PYRIDAZINONES AS MEDICAMENTS AND PHARMACEUTICAL COMPOSITIONS COMPRISING THEM |
| AR057986A1 (en) | 2005-11-21 | 2008-01-09 | Japan Tobacco Inc | HETEROCICLICAL COMPOUND AND ITS PHARMACEUTICAL USE |
| US20100210649A1 (en) * | 2006-12-21 | 2010-08-19 | Sloan-Kettering Institute For Cancer Research | Pyridazinones and furan-containing compounds |
| EP2328586A2 (en) | 2008-05-20 | 2011-06-08 | Cephalon, Inc. | Substituted pyridazinone derivatives as histamine-3 (h3) receptor ligands |
| PE20100362A1 (en) | 2008-10-30 | 2010-05-27 | Irm Llc | PURINE DERIVATIVES THAT EXPAND HEMATOPOYETIC STEM CELLS |
| BR112013002079B1 (en) | 2010-07-27 | 2021-09-14 | Trustees Of Boston University | ARIL HYDROCARBIDE (AHR) RECEIVER MODIFIERS AS NEW CANCER THERAPEUTICS |
| WO2015143164A1 (en) | 2014-03-19 | 2015-09-24 | President And Fellows Of Harvard College | Antimicrobial agents and screening methods |
| CN109863140B (en) * | 2016-05-25 | 2023-02-21 | 拜耳医药股份有限公司 | 3-oxo-2, 6-diphenyl-2, 3-dihydropyridazine-4-carboxamide |
| JOP20190193A1 (en) | 2017-02-09 | 2019-08-08 | Bayer Pharma AG | 2-heteroaryl-3-oxo-2,3-dihydropyridazine-4-carboxamides for the treatment of cancer |
| CA3082856A1 (en) | 2017-11-21 | 2019-05-31 | Bayer Aktiengesellschaft | Sulphur substituted 3-oxo-2,3-dihydropyridazine-4-carboxamides |
-
2017
- 2017-06-16 JO JOP/2019/0193A patent/JOP20190193A1/en unknown
-
2018
- 2018-02-02 CA CA3052718A patent/CA3052718A1/en active Pending
- 2018-02-02 AU AU2018217860A patent/AU2018217860B2/en active Active
- 2018-02-02 PL PL18703958T patent/PL3580211T3/en unknown
- 2018-02-02 LT LTEP18703958.1T patent/LT3580211T/en unknown
- 2018-02-02 RS RS20210096A patent/RS61401B1/en unknown
- 2018-02-02 SG SG11201907232XA patent/SG11201907232XA/en unknown
- 2018-02-02 MA MA47447A patent/MA47447B1/en unknown
- 2018-02-02 HU HUE18703958A patent/HUE053191T2/en unknown
- 2018-02-02 KR KR1020197025958A patent/KR102627266B1/en active IP Right Grant
- 2018-02-02 CN CN202310485656.6A patent/CN116554152A/en active Pending
- 2018-02-02 CN CN202310479983.0A patent/CN116531380A/en active Pending
- 2018-02-02 CU CU2019000073A patent/CU24564B1/en unknown
- 2018-02-02 GE GEAP201815183A patent/GEP20217281B/en unknown
- 2018-02-02 PE PE2019001570A patent/PE20191496A1/en unknown
- 2018-02-02 DK DK18703958.1T patent/DK3580211T3/en active
- 2018-02-02 UA UAA201909559A patent/UA124507C2/en unknown
- 2018-02-02 WO PCT/EP2018/052627 patent/WO2018146010A1/en unknown
- 2018-02-02 CN CN201880024008.8A patent/CN110678459B/en active Active
- 2018-02-02 JP JP2019542502A patent/JP7128826B2/en active Active
- 2018-02-02 ES ES18703958T patent/ES2847162T3/en active Active
- 2018-02-02 EP EP18703958.1A patent/EP3580211B1/en active Active
- 2018-02-02 MX MX2019009571A patent/MX2019009571A/en unknown
- 2018-02-02 BR BR112019016497A patent/BR112019016497A2/en unknown
- 2018-02-02 SI SI201830192T patent/SI3580211T1/en unknown
- 2018-02-02 CR CR20190364A patent/CR20190364A/en unknown
- 2018-02-05 TW TW107104035A patent/TWI770113B/en active
- 2018-02-09 UY UY0001037606A patent/UY37606A/en unknown
-
2019
- 2019-08-04 IL IL268469A patent/IL268469B/en unknown
- 2019-08-08 SA SA519402422A patent/SA519402422B1/en unknown
- 2019-08-08 PH PH12019501846A patent/PH12019501846A1/en unknown
- 2019-08-09 DO DO2019000206A patent/DOP2019000206A/en unknown
- 2019-08-09 NI NI201900085A patent/NI201900085A/en unknown
- 2019-08-09 CO CONC2019/0008684A patent/CO2019008684A2/en unknown
- 2019-08-09 CL CL2019002255A patent/CL2019002255A1/en unknown
- 2019-08-12 EC ECSENADI201957713A patent/ECSP19057713A/en unknown
- 2019-09-06 ZA ZA2019/05902A patent/ZA201905902B/en unknown
-
2021
- 2021-01-27 HR HRP20210143TT patent/HRP20210143T1/en unknown
- 2021-01-28 CY CY20211100070T patent/CY1124484T1/en unknown
-
2022
- 2022-08-12 US US17/819,602 patent/US11795164B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11201907232XA (en) | 2-heteroaryl-3-oxo-2,3-dihydropyridazine-4-carboxamides for the treatment of cancer | |
| SG11201810366WA (en) | 3-oxo-2,6-diphenyl-2,3-dihydropyridazine-4-carboxamides | |
| SG11202000266VA (en) | Quinoline derivatives for treating infections with helminths | |
| SG11201809126RA (en) | Aromatic sulfonamide derivatives | |
| SG11201903059SA (en) | New anthelmintic quinoline-3-carboxamide derivatives | |
| SG11201806863WA (en) | Tetracyclic pyridone compounds as antivirals | |
| SG11201811737SA (en) | Novel fatty acid modified urocortin-2 analogs for the treatment of diabetes and chronic kidney disease | |
| SG11201808214TA (en) | Pyrazolopyrimidine derivatives | |
| SG11201811448RA (en) | Dihydropyranopyrimidines for the treatment of viral infections | |
| SG11201901206SA (en) | Trimer stabilizing hiv envelope protein mutations | |
| SG11201901633WA (en) | 7-substituted sulfonimidoylpurinone compounds for the treatment and prophylaxis of virus infection | |
| SG11201902531QA (en) | Liquid pharmaceutical composition | |
| SG11201811706RA (en) | Process for the preparation of microcapsules | |
| SG11201807913XA (en) | Stabilized soluble pre-fusion rsv f proteins | |
| SG11201808566WA (en) | Polymorphic form of n-{6-(2-hydroxypropan-2-yl)-2-[2-(methylsulphonyl)ethyl]-2h-indazol-5-yl}-6-(trifluoromethyl)pyridine-2-carboxamide | |
| SG11201809470RA (en) | Substituted indazoles useful for treatment and prevention of allergic and/or inflammatory diseases in animals | |
| SG11201906436VA (en) | Novel heterocyclic compound, its preparation method, and pharmaceutical composition comprising the same | |
| SG11201901374WA (en) | Antibiotic compounds | |
| SG11201811230RA (en) | Compositions and methods for reducing ocular neovascularization | |
| SG11201909243TA (en) | New bicyclic pyrazole derivatives | |
| SG11201811671XA (en) | Prins reaction and intermediates useful in the synthesis of halichondrin macrolides and analogs thereof | |
| SG11201809537VA (en) | Urea motif containing compounds and derivatives thereof as antibacterial drugs | |
| SG11201810078PA (en) | Stabilized pre-fusion rsv f proteins | |
| SG11201901817SA (en) | Blood-brain barrier-penetrant dopamine-b-hydroxylase inhibitors | |
| SG11201808686VA (en) | Synthesis of indazoles |